Parmax Pharma Ltd — Results, 14-08-2025: Result

Parmax Pharma's board has approved the financial results for the quarter ended June 30, 2025. The company reported a net loss of ₹0.76 Cr on a revenue of ₹1.94 Cr for the quarter. Additionally, the board appointed Mr. Samsad Alam Khan as the Secretarial Auditor for a five-year term, pending shareholder approval. This appointment enhances the company's governance framework. These updates are key for shareholders to track financial performance and corporate compliance.